Artemisia annua, Hyb8001r
This website provides information about a new variety of Artemisia annua, Hyb8001r, which is available for purchase from East-West Seed International
The medicinal plant Artemisia annua produces artemisinin, the active ingredient for anti-malaria drugs called Artemisinin Combination Therapies (ACTs).
Malaria is a major global health problem: there were 212 million new cases of malaria in 2015 and an estimated 429,000 malaria deaths. The greatest malaria burden is for the African region.
Centre for Novel Agricultural Products, University of York
CNAP is a research centre in the Department of Biology. Our aim is to undertake research that benefits society. Read more here.
The CNAP Artemisia Research Project is directed by Professor Ian Graham and is funded by the Bill & Melinda Gates Foundation.
Ian Graham, CNAP: "This project demonstrates how world-class, strategic research can be delivered with impact for the benefit of developing countries. Our commercialisation partnership with East-West Seed International continues to enable global access to our new hybrid variety through the availability of low-cost, quality seed."
East-West Seed International
East-West Seed International is our commercialisation partner. They provide sustainable, large-scale seed production and distribution of our Artemisia annua F1 hybrids.
Bert van der Feltz, CEO of East-West Seed: “We are pleased to be in a position to produce and supply F1 hybrid seed for this essential medicinal crop. We share in the commitment of CNAP and the Bill & Melinda Gates Foundation to eradicate malaria globally. I am thankful that we can contribute to saving millions of lives through this partnership.”
East-West Seed were the first to demonstrate field-based A. annua hybrid seed production, substantially reducing the costs of hybrid seed. Read more here